Baluapuri A, Wolf E, Eilers M. Target gene-independent functions of MYC oncoproteins. Nat Rev Mol Cell Biol. 2020;21(5):255–67.

CAS  PubMed  PubMed Central  Google Scholar 

Lourenco C, Resetca D, Redel C, Lin P, MacDonald AS, Ciaccio R, et al. MYC protein interactors in gene transcription and cancer. Nat Rev Cancer. 2021;21(9):579–91.

CAS  PubMed  Google Scholar 

Dhanasekaran R, Deutzmann A, Mahauad-Fernandez WD, Hansen AS, Gouw AM, Felsher DW. The MYC oncogene - the grand orchestrator of cancer growth and immune evasion. Nat Rev Clin Oncol. 2022;19(1):23–36.

CAS  PubMed  Google Scholar 

Amjadi-Moheb F, Paniri A, Akhavan-Niaki H. Insights into the links between MYC and 3D chromatin structure and epigenetics regulation: implications for cancer therapy. Cancer Res. 2021;81(8):1925–36.

CAS  PubMed  Google Scholar 

Zacarías-Fluck MF, Soucek L, Whitfield JR. MYC: there is more to it than cancer. Front Cell Dev Biol. 2024;12: 1342872.

PubMed  PubMed Central  Google Scholar 

Gabay M, Li Y, Felsher DW. MYC activation is a hallmark of cancer initiation and maintenance. Cold Spring Harb Perspect Med. 2014;4(6): a014241.

PubMed  PubMed Central  Google Scholar 

Tate JG, Bamford S, Jubb HC, Sondka Z, Beare DM, Bindal N, et al. COSMIC: the catalogue of somatic mutations in cancer. Nucleic Acids Res. 2019;47(D1):D941–7.

CAS  PubMed  Google Scholar 

Love C, Sun Z, Jima D, Li G, Zhang J, Miles R, Richards KL, et al. The genetic landscape of mutations in Burkitt lymphoma. Nat Genet. 2012;44(12):1321–5.

CAS  PubMed  PubMed Central  Google Scholar 

Dang CV. Myc on the path to cancer. Cell. 2012;149(1):22–35.

CAS  PubMed  PubMed Central  Google Scholar 

Littlewood TD, Kreuzaler P, Evan GI. All things to all people. Cell. 2012; 28;151(1):11-3.

Wolpaw AJ, Dang CV. MYC-induced metabolic stress and tumorigenesis. Biochim Biophys Acta Rev Cancer. 2018;1870(1):43–50.

CAS  PubMed  Google Scholar 

Jakobsen ST, Jensen RAM, Madsen MS, Ravnsborg T, Vaagenso CS, Siersbæk MS, et al. MYC activity at enhancers drives prognostic transcriptional programs through an epigenetic switch. Nat Genet. 2024;56(4):663–74.

CAS  PubMed  Google Scholar 

Wanzel M, Herold S, Eilers M. Transcriptional repression by Myc. Trends Cell Biol. 2003;13(3):146–50.

CAS  PubMed  Google Scholar 

Walz S, Lorenzin F, Morton J, Wiese KE, von Eyss B, Herold S, et al. Activation and repression by oncogenic MYC shape tumour-specific gene expression profiles. Nature. 2014;511(7510):483–7.

CAS  PubMed  PubMed Central  Google Scholar 

Vo BT, Wolf E, Kawauchi D, Gebhardt A, Rehg JE, Finkelstein D, et al. The interaction of MYC with MIZ1 defines medulloblastoma subgroup identity. Cancer Cell. 2016;29(1):5–16.

CAS  PubMed  PubMed Central  Google Scholar 

Das SK, Lewis BA, Levens D. MYC: a complex problem. Trends Cell Biol. 2022;S0962–8924(22):00176–83.

Google Scholar 

Gnanaprakasam JN, Wang R. MYC in regulating immunity: metabolism and beyond. Genes (Basel). 2017;8(3): 88.

PubMed  Google Scholar 

Casey SC, Baylot V, Felsher DW. MYC: master regulator of immune privilege. Trends Immunol. 2017;38(4):298–305.

CAS  PubMed  PubMed Central  Google Scholar 

Sodir NM, Kortlever RM, Barthet VJA, Campos T, Pellegrinet L, Kupczak S, et al. MYC instructs and maintains pancreatic adenocarcinoma phenotype. Cancer Discov. 2020;10(4):588–607.

CAS  PubMed  Google Scholar 

Kortlever RM, Sodir NM, Wilson CH, Burkhart DL, Pellegrinet L, Brown Swigart L, et al. Myc cooperates with ras by programming inflammation and immune suppression. Cell. 2017;171(6):1301-1315.e14.

CAS  PubMed  PubMed Central  Google Scholar 

Zimmerli D, Brambillasca CS, Talens F, Bhin J, Linstra R, Romanens L, et al. MYC promotes immune-suppression in triple-negative breast cancer via inhibition of interferon signaling. Nat Commun. 2022;13(1): 6579.

CAS  PubMed  PubMed Central  Google Scholar 

Lee KM, Lin CC, Servetto A, Bae J, Kandagatla V, Ye D, et al. Epigenetic repression of STING by MYC promotes immune evasion and resistance to immune checkpoint inhibitors in triple-negative breast cancer. Cancer Immunol Res. 2022;10(7):829–43.

CAS  PubMed  PubMed Central  Google Scholar 

Lee JV, Housley F, Yau C, Nakagawa R, Winkler J, Anttila JM, et al. Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer. Nat Commun. 2022;3(1):3671.

Google Scholar 

Dhanasekaran R, Hansen AS, Park J, Lemaitre L, Lai I, Adeniji N, et al. MYC overexpression drives immune evasion in hepatocellular carcinoma that is reversible through restoration of proinflammatory macrophages. Cancer Res. 2023;83(4):626–40.

CAS  PubMed  PubMed Central  Google Scholar 

Casey SC, Tong L, Li Y, Do R, Walz S, Fitzgerald KN, et al. MYC regulates the antitumor immune response through CD47 and PD-L1. Science. 2016;352(6282):227–31.

CAS  PubMed  PubMed Central  Google Scholar 

Versteeg R, Noordermeer IA, Krüse-Wolters M, Ruiter DJ, Schrier PI. c-Myc down-regulates class I HLA expression in human melanomas. EMBO J. 1988;7(4):1023–9.

CAS  PubMed  PubMed Central  Google Scholar 

Peltenburg LT, Dee R, Schrier PI. Downregulation of HLA class I expression by c-myc in human melanoma is independent of enhancer A. Nucleic Acids Res. 1993;21(5):1179–85.

CAS  PubMed  PubMed Central  Google Scholar 

Griffioen M, Steegenga WT, Ouwerkerk IJ, Peltenburg LT, Jochemsen AG, Schrier PI. Repression of the minimal HLA-B promoter by c-myc and p53 occurs through independent mechanisms. Mol Immunol. 1998;35(13):829–35.

CAS  PubMed  Google Scholar 

Wu SY, Xiao Y, Wei JL, Xu XE, Jin X, Hu X, et al. MYC suppresses STING-dependent innate immunity by transcriptionally upregulating DNMT1 in triple-negative breast cancer. J Immunother Cancer. 2021;9(7): e002528.

PubMed  PubMed Central  Google Scholar 

Swaminathan S, Hansen AS, Heftdal LD, Dhanasekaran R, Deutzmann A, Fernandez WDM, et al. MYC functions as a switch for natural killer cell-mediated immune surveillance of lymphoid malignancies. Nat Commun. 2020;11(1): 2860.

CAS  PubMed  PubMed Central  Google Scholar 

Dejure FR, Eilers M. MYC and tumor metabolism: chicken and egg. EMBO J. 2017;36(23):3409–20.

CAS  PubMed  PubMed Central  Google Scholar 

Li G, Choi JE, Kryczek I, Sun Y, Liao P, Li S, et al. Intersection of immune and oncometabolic pathways drives cancer hyperprogression during immunotherapy. Cancer Cell. 2023;41(2):304-322.e7.

CAS  PubMed  PubMed Central  Google Scholar 

Dang CV, Le A, Gao P. MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin Cancer Res. 2009;15(21):6479–83.

CAS  PubMed  PubMed Central  Google Scholar 

Smith BAH, Deutzmann A, Correa KM, Delaveris CS, Dhanasekaran R, Dove CG, et al. MYC-driven synthesis of Siglec ligands is a glycoimmune checkpoint. Proc Natl Acad Sci U S A. 2023;120(11): e2215376120.

CAS  PubMed  PubMed Central  Google Scholar 

Sears R, Leone G, DeGregori J, Nevins JR. Ras enhances Myc protein stability. Mol Cell. 1999;3(2):169–79.

CAS  PubMed  Google Scholar 

Leone G, DeGregori J, Sears R, Jakoi L, Nevins JR. Myc and Ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F. Nature. 1997;387(6631):422–6.

CAS  PubMed  Google Scholar 

Wang J, Merino DM, Light N, Murphy BL, Wang YD, Guo X, et al. Myc and loss of p53 cooperate to drive formation of choroid plexus carcinoma. Cancer Res. 2019;79(9):2208–19.

CAS  PubMed